View Navigation Search Our Site

A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic colorectal Cancer

Purpose

This phase II trial studies how well savolitinib works in treating participants with MET amplified colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility

  • Ages: 18 and older
  • Sexes: All
  • Accepts healthy volunteers?: No
For additional eligibility criteria, please contact the study team.

Procedures

Participants receive savolitinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up at 30 days, and then every 12 weeks thereafter.

Contact the study team

Additional eligibility criteria and study procedure details can be explained by the study team. Please call or email:

Thomas George
Phone: 352.273.8010
Email: cancer-center@ufl.edu

Age

18 to 65
65 and over

Gender

Male
Female

Keywords

Colorectal cancer

Principal Investigator

Thomas George, MD, FACP

Department

Oncology

Contact Information

cancer-center@ufl.edu

352.273.8010

Begin a new search for other research studies

Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams